Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus

Chin-Hsiao Tseng

doi:10.18632/oncotarget.13824

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus

Chin-Hsiao Tseng _

PDF | HTML | How to cite

Oncotarget. 2017; 8:3042-3048. https://doi.org/10.18632/oncotarget.13824

Metrics: PDF 2075 views | HTML 2523 views | ?

Abstract

Chin-Hsiao Tseng1,2,3

1Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan

2Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

3Division of Environmental Health and Occupational Medicine of the National Health Research Institutes, Zhunan, Taiwan

Correspondence to:

Chin-Hsiao Tseng, email: [email protected]

Keywords: breast cancer, diabetes mellitus, rosiglitazone, Taiwan

Received: October 09, 2016 Accepted: November 30, 2016 Published: December 08, 2016

ABSTRACT

This study investigated whether rosiglitazone may affect breast cancer risk in female patients with type 2 diabetes mellitus in Taiwan. The reimbursement database of all female patients with type 2 diabetes mellitus under oral antidiabetic agents or insulin from 1996 to 2009 was retrieved from the National Health Insurance. An entry date was set on 1 January 2006 and a total of 431447 patients were followed up for breast cancer incidence till the end of 2009. Incidences for ever users, never users and subgroups of rosiglitazone dose-response parameters (tertile cutoffs of cumulative duration and cumulative dose) were calculated and hazard ratios estimated by Cox regression. There were 53029 ever users and 378418 never users, respective numbers of incident breast cancer 410 (0.77%) and 3292 (0.87%), and respective incidence 217.53 and 249.12 per 100000 person-years. The overall hazard ratio was 0.889 (95% confidence interval: 0.797−0.992) in the fully adjusted model. Significantly lower risk was observed for the third tertiles of cumulative duration (> 14 months) and cumulative dose (> 1792 mg) while compared to never users, with respective adjusted hazard ratio of 0.815 (95% confidence interval: 0.682−0.973) and 0.815 (95% confidence interval: 0.682−0.974). Additionally, a significant interaction between metformin and rosiglitazone was observed. The lowest risk was seen in patients who used both drugs (hazard ratio 0.812, 95% confidence interval: 0.705−0.934). In conclusion, rosiglitazone reduces breast cancer risk in female patients with type 2 diabetes mellitus, which shows a significant interaction with metformin.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13824

Publication Alerts

Research Papers:

Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus

Abstract